Hypertension in dialysis

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 2, 2005, Pages 111-118

  Santos, Sergio F F ^a   Peixoto, Aldo J ^b,c,d  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d Renal Section   (United States)

Author keywords

Cardiovascular disease; Hemodialysis; Hypertension; Peritoneal dialysis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINE OXIDASE (FLAVIN CONTAINING); AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; LISINOPRIL; MINERALOCORTICOID ANTAGONIST; MINOXIDIL; RENALASE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIALYSATE; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORTALITY; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; SALT INTAKE; SLEEP APNEA SYNDROME; SODIUM BLOOD LEVEL; WATER RETENTION;

EID: 15444378197     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200503000-00005     Document Type: Review

References (79)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
2. Santos SF, Mendes RB, Santos CA, et al. Profile of interdialytic blood pressure in hemodialysis patients. Am J Nephrol 2003; 23:96-105. Detailed description of ambulatory blood pressure profiles in hemodialysis patients.
3. Mendes RB, Santos SF, Dorigo D, et al. The use of peridialysis blood pressure and intradialytic blood pressure changes in the prediction of interdialytic blood pressure in haemodialysis patients. Blood Press Monit 2003; 8:243-248. Paper exploring the prediction of interdialytic blood pressure by peridialysis readings, demonstrating that the behavior of blood pressure during hemodialysis alters prediction.
4. Rodby RA, Vonesh EF, Korbet SM. Blood pressures in hemodialysis and peritoneal dialysis using ambulatory blood pressure monitoring. Am J Kidney Dis 1994; 23:401-411.
5. Agarwal R, Lewis RR. Prediction of hypertension in chronic hemodialysis patients. Kidney Int 2001; 60:1982-1989.
6. Lazar AE, Smith MC, Rahman M. Blood pressure measurement in hemodialysis patients. Semin Dial 2004; 17:250-254.
7. Agarwal R. Assessment of blood pressure in hemodialysis patients. Semin Dial 2002; 15:299-304.
8. Sankaranarayanan N, Santos SFF, Peixoto AJ. Blood pressure measurement in dialysis patients. Adv Chr Kidney Dis 2004; 11:134-142.
9. Rahman M, Griffin V, Kumar A, et al. A comparison of standardized versus "usual" blood pressure measurements in hemodialysis patients. Am J Kidney Dis 2002; 39:1226-1230.
10. Peixoto AJ, Santos SF, Mendes RB, et al. Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 2000; 36:983-990.
11. Peixoto AJ, White WB. Ambulatory blood pressure monitoring in chronic renal disease: technical aspects and clinical relevance. Curr Opin Nephrol Hypertens 2002; 11:507-516.
12. Amar J, Vernier I, Rossignol E, et al. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000; 57:2485-2491.
13. Liu M, Takahashi H, Morita Y, et al. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant 2003; 18:563-569. Non-dipping on ABPM predicts cardiovascular events and mortality in hemodialysis patients.
14. Covic A, Goldsmith DJ, Covic M. Reduced blood pressure diurnal variability as a risk factor for progressive left ventricular dilatation in hemodialysis patients. Am J Kidney Dis 2000; 35:617-623.
15. Agarwal R. Role of home blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 1999; 33:682-687.
16. Horl MP, Horl WH. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002; 39:227-244.
17. Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115:291-297.
18. Cheigh JS, Milite C, Sullivan JF, et al. Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis 1992; 19:453-459.
19. Cannella G, Paoletti E, Ravera G, et al. Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients. Kidney Int 2000; 58:260-268.
20. Zager PG, Nikolic J, Brown RH, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54:561-569.
21. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33:507-517.
22. Salem MM, Bower J. Hypertension in the hemodialysis population: any relation to one-year survival? Am J Kidney Dis 1996; 28:737-740.
23. Zoccali C. Arterial pressure components and cardiovascular risk in end-stage renal disease. Nephrol Dial Transplant 2003; 18:249-252. Thoughtful review on the topic. Of special relevance is the presentation of preliminary results from the CREED study.
24. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58:2147-2154.
25. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14:3270-3277. Hypertension is associated with decreased mortality in the first year of dialysis, but not thereafter.
26. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62:1784-1790.
27. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287:1548-1555.
28. Lucas MF, Quereda C, Teruel JL, et al. Effect of hypertension before beginning dialysis on survival of hemodialysis patients. Am J Kidney Dis 2003; 41:814-821. Uncontrolled hypertension before the initiation of dialysis is associated with increased cardiovascular mortality at follow up.
29. Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49:1379-1385.
30. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. N Engl J Med 1969; 280:978-981.
31. Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol 1996; 16:35-44.
32. Charra B, Bergstrom J, Scribner BH. Blood pressure control in dialysis patients: importance of the lag phenomenon. Am J Kidney Dis 1998; 32:720-724.
33. Khosla UM, Johnson RJ. Hypertension in the hemodialysis patient and the "lag phenomenon": insights into pathophysiology and clinical management. Am J Kidney Dis 2004; 43:739-751. Interesting review proposing the role of asymmetric dimethylarginine and ouabain-like factors in understanding the delays in achieving blood pressure control following achievement of dry weight.
34. Katzarski KS, Charra B, Luik AJ, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999; 14:369-375.
35. Luik AJ, van der Sande FM, Weideman P, et al. The influence of increasing dialysis treatment time and reducing dry weight on blood pressure control in hemodialysis patients: a prospective study. Am J Nephrol 2001; 21:471-478.
36. Chan CT, Floras JS, Miller JA, et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61:2235-2239.
37. Nesrallah G, Suri R, Moist L, et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 2003; 42(suppl 1):13-17. Description of the effects of daily dialysis (short and nocturnal) on volume and blood pressure control in the London, Ontario (Canada) experience.
38. Khandelwal M, Oreopoulos D. Sodium and volume overload in peritoneal dialysis: limitations of current treatment and possible solutions. Int Urol Nephrol 2004; 36:101-107. Current review of relevant factors related to volume and blood pressure control in peritoneal dialysis.
39. Saldanha LF, Weiler EW, Gonick HC. Effect of continuous ambulatory peritoneal dialysis on blood pressure control. Am J Kidney Dis 1993; 21:184-188.
40. Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63:1556-1563. Icodextrin improves blood pressure, volume control and left-ventricular hypertrophy in high-transporter peritoneal dialysis patients.
41. Flanigan M. Dialysate composition and hemodialysis hypertension. Semin Dial 2004; 17:279-283. Insightful review on the topic.
42. Flanigan MJ. Sodium flux and dialysate sodium in hemodialysis. Semin Dial 1998; 11:298-304.
43. Flanigan MJ. Role of sodium in hemodialysis. Kidney Int Suppl 2000; 76:872-S78.
44. Lopot F, Blaha J, Valek A. An equation for calculating postdialysis plasma sodium. Int J Artif Organs 1992; 15:354-357.
45. Levin NW, Zhu F, Keen M. Interdialytic weight gain and dry weight. Blood Purif 2001; 19:217-221.
46. De Paula FM, Peixoto AJ, Pinto LV, et al. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int 2004; 66:1232-1238. The use of an individualized sodium dialysate prescription (matching the patient's own pre-dialysis serum sodium) resulted in better blood pressure control in patients with previously uncontrolled blood pressure.
47. Blaustein MP. Endogenous ouabain: role in the pathogenesis of hypertension. Kidney Int 1996; 49:1748-1753.
48. Ozkahya M, Toz H, Qzerkan F, et al. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 2002; 15:655-660.
49. Krautzig S, Janssen U, Koch KM, et al. Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. Nephrol Dial Transplant 1998; 13:552-553.
50. Kyriazis J, Glotsos J, Bilirakis L, et al. Dialysate calcium profiling during hemodialysis: use and clinical implications. Kidney Int 2002; 61:276-287.
51. Kyriazis J, Kalogeropoulou K, Bilirakis L, et al. Dialysate magnesium level and blood pressure. Kidney Int 2004; 66:1221-1231. Higher dialysate magnesium concentration improves intradialytic hemodynamic stability.
52. Dolson GM, Ellis KJ, Bernardo MV, et al. Acute decreases in serum potassium augment blood pressure. Am J Kidney Dis 1995; 26:321-326.
53. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43:699-706. Concise, up-to-date review of the topic.
54. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
55. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359.
56. Xu J, Li G, Wang P, et al. Renalase: a novel, soluble monoamine oxidase that regulates blood pressure. J Am Soc Nephrol 2004; 15:642A.
57. Ishani A, Herzog CA, Collins AJ, Foley RN. Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Kidney Int 2004; 65:1017-1025. Analysis of the associations between cardiovascular drug use and mortality in the Dialysis Morbidity and Mortality Study.
58. Griffith TF, Chua BS, Allen AS, et al. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003; 42:1260-1269. Detailed analysis of hypertension treatment and its impact on outcomes in the Dialysis Morbidity and Mortality Study.
59. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41:1438-1444. Well-conducted prospective, randomized, blinded trial showing a survival advantage of carvedilol in patients with dilated cardiomyopathy on dialysis.
60. Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 2002; 13:729-733.
61. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. J Hypertens 2001; 19:287-293.
62. Zoccali C, Benedetto FA, Tripepi G, et al. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int 1998; 53:1078-1084.
63. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344:102-107.
64. Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9:859-868.
65. Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting "daily" hemodialysis. Kidney Int 1999; 55:2467-2476.
66. Chan CT, Harvey PJ, Picton P, et al. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003; 42:925-931. Important mechanistic study evaluating the effects of nocturnal dialysis on vascular regulation and function.
67. Stoves J, Baczkowski AJ, Turney JH. Factors influencing survival of diabetic patients after initiation of renal replacement therapy. Nephrology Carlton 2001; 2001:79-84.
68. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40:1023-1029.
69. Cannella G, Paoletti E, Delfino R, et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30:659-664.
70. Shibasaki Y, Masaki H, Nishiue T, et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90:256-261.
71. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 2004; 8:320-327. Combination enalapril/losartan provides small additive benefit on regression of left-ventricular hypertrophy in hemodialysis patients with diabetes.
72. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103:987-992.
73. Lndon GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996; 50:600-608.
74. Li PK, Chow KM, Wong TY, et al. Effects of angiotensin converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139:105-112.
75. Agarwal R, Lewis R, Davis JL, Becker B. Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 2001; 38:1245-1250.
76. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999; 55:1528-1535.
77. Ross EA, Pittman TB, Koo LC. Strategy for the treatment of noncompliant hypertensive hemodialysis patients. Int J Artif Organs 2002; 25:1061-1065.
78. Kestenbaum B, Gillen DL, Sherrard DJ, et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002; 61:2157-2164.
79. Rastogi SP, Volans G, Elliott RW, et al. High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure. Postgrad Med J 1971; 47(suppl):45-53.